PassPort Technologies
PassPort Technologies is a cutting-edge biotechnology company committed to the swift development and patient delivery of exceptional pharmaceuticals through its proprietary PassPort system. Located in San Diego, California, the company focuses on developing advanced drug delivery systems to improve global health outcomes. It collaborates with various partners, including academic institutions and pharmaceutical companies, to innovate in drug delivery and therapeutics. The company is also exploring future medication management and patient adherence solutions, integrating new wireless communication and data management technologies.
Industries
Nr. of Employees
small (1-50)
PassPort Technologies
Patents
Products
Transdermal microporation delivery platform
A platform technology that facilitates active transdermal delivery by creating micropores in the skin to enable rapid systemic absorption of therapeutic agents.
Transdermal zolmitriptan candidate (early clinical)
A transdermal formulation candidate of zolmitriptan evaluated in early-phase clinical testing that demonstrated rapid plasma detection and increased relative bioavailability versus oral tablet in interim results.
Transdermal microporation delivery platform
A platform technology that facilitates active transdermal delivery by creating micropores in the skin to enable rapid systemic absorption of therapeutic agents.
Transdermal zolmitriptan candidate (early clinical)
A transdermal formulation candidate of zolmitriptan evaluated in early-phase clinical testing that demonstrated rapid plasma detection and increased relative bioavailability versus oral tablet in interim results.
Services
Formulation, screening and preclinical evaluation services to assess transdermal delivery feasibility for partner compounds.
Co-development programs with academic and industry partners to advance preclinical research and early clinical development of transdermal therapeutics.
Formulation, screening and preclinical evaluation services to assess transdermal delivery feasibility for partner compounds.
Co-development programs with academic and industry partners to advance preclinical research and early clinical development of transdermal therapeutics.
Expertise Areas
- Transdermal drug delivery
- Clinical trial management (early-phase)
- Formulation development for transdermal systems
- Medical device development for drug delivery
Key Technologies
- Transdermal microporation
- Active transdermal delivery systems
- Lipid-mediated mRNA delivery (collaborative application)
- Pharmacokinetic bioavailability assays
News & Updates
PassPort Technologies announced positive interim results from the Phase 1 clinical trial of Zolmitriptan PassPort®, which utilized its proprietary transdermal microporation system to treat acute migraine. The system showed faster plasma detection and higher bioavailability compared to oral tablets.
The company initiated a US Phase 1 clinical study of Zolmitriptan PassPort® utilizing its proprietary transdermal microporation system for the treatment of acute migraine, focusing on safety and pharmacokinetics.
The collaboration combines PassPort's transdermal drug delivery technology with Arcturus's LUNAR® lipid-mediated delivery technology to develop new options for mRNA vaccines and therapeutics.
PassPort Technologies and IP Gaia entered into a strategic business agreement to enhance activities around PassPort's transdermal platform technology and pipeline.
PassPort Technologies was named a Top 10 Drug Delivery Solution Provider in 2022 by Medical Tech Outlook for its innovative drug delivery solutions.
A collaborative research with Josai University resulted in a publication in the European Journal of Pharmaceutical Sciences, utilizing PassPort's delivery platform to improve skin permeation and transdermal absorption.
PassPort Technologies announced positive interim results from the Phase 1 clinical trial of Zolmitriptan PassPort®, which utilized its proprietary transdermal microporation system to treat acute migraine. The system showed faster plasma detection and higher bioavailability compared to oral tablets.
The company initiated a US Phase 1 clinical study of Zolmitriptan PassPort® utilizing its proprietary transdermal microporation system for the treatment of acute migraine, focusing on safety and pharmacokinetics.
The collaboration combines PassPort's transdermal drug delivery technology with Arcturus's LUNAR® lipid-mediated delivery technology to develop new options for mRNA vaccines and therapeutics.
PassPort Technologies and IP Gaia entered into a strategic business agreement to enhance activities around PassPort's transdermal platform technology and pipeline.
PassPort Technologies was named a Top 10 Drug Delivery Solution Provider in 2022 by Medical Tech Outlook for its innovative drug delivery solutions.
A collaborative research with Josai University resulted in a publication in the European Journal of Pharmaceutical Sciences, utilizing PassPort's delivery platform to improve skin permeation and transdermal absorption.